《大行报告》中金首予亚盛医药-B(06855.HK)「跑赢行业」评级 目标价60元
中金发表研究报告,首次覆盖亚盛医药-B(06855.HK)予「跑赢行业」评级,目标价60元。该行指,公司为专注於细胞凋亡创新药物,科学驱动研发型生物科技企业,其有望通过其差异化的产品以及中美同时开发的临床策略,能够更快地将公司的潜力新型原创小分子药物推向全球市场,国际化潜力出众。
报告称,其後期临床阶段候选药物市场前景广阔,已建立了丰富且差异化的研发管线。该行料其2021及2022年每股亏损分别3.9元及1.51元人民币。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.